➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Baxter
Express Scripts
Dow

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AG-348


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug AG-348?

AG-348 is an investigational drug.

There have been 15 clinical trials for AG-348. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2021.

The most common disease conditions in clinical trials are Pyruvate Metabolism, Inborn Errors, Anemia, Hemolytic, Congenital Nonspherocytic, and Thalassemia. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI), and [disabled in preview].

There are seven US patents protecting this investigational drug and one hundred and three international patents.

Recent Clinical Trials for AG-348
TitleSponsorPhase
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)Agios Pharmaceuticals, Inc.Phase 3
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Agios Pharmaceuticals, Inc.Phase 3
A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult ParticipantsAgios Pharmaceuticals, Inc.Phase 1

See all AG-348 clinical trials

Clinical Trial Summary for AG-348

Top disease conditions for AG-348
Top clinical trial sponsors for AG-348

See all AG-348 clinical trials

US Patents for AG-348

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-348   Get Started Free Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. (Cambridge, MA)   Get Started Free
AG-348   Get Started Free Pyruvate kinase activators for use in therapy Agios Pharmaceuticals, Inc. (Cambridge, MA)   Get Started Free
AG-348   Get Started Free Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. (Cambridge, MA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Medtronic
Boehringer Ingelheim
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.